Sacituzumab and brain radiation for EGFR lung cancer with brain mets
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies a new drug called sacituzumab tirumotecan combined with brain radiation for people with EGFR-positive lung cancer that has spread to the brain and has grown despite targeted therapy. The goal is to see if this combination can better control the brain tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with a type of lung cancer called non-squamous non-small cell lung cancer (NSCLC).
- You have brain metastases that are visible on imaging and need radiation.
- Your tumor has an EGFR mutation (like exon 19 deletion or L858R).
- You have already been treated with a third-generation EGFR inhibitor (e.g., osimertinib) and the cancer progressed in the brain.
- You have not had prior brain radiation and do not have leptomeningeal disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding nitroglycerin (a medicine that widens blood vessels) to standard whole-brain radiation helps improve treatment for lung cancer that has spread to the brain. It is for people with a specific gene change (EGFR mutation) in their cancer.
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
This study tests a new combination of drugs (sacituzumab tirumotecan plus a third-generation EGFR inhibitor) with or without radiation therapy for advanced lung cancer that has spread to the brain after prior EGFR inhibitor treatment. The goal is to see if this combination can better control the cancer and improve outcomes for patients with brain metastases.
This trial tests a combination of two drugs, sacituzumab tirumotecan and bevacizumab, for people with EGFR-mutant lung cancer that has spread to the brain. It aims to see if this combination can shrink tumors and improve outcomes after standard EGFR inhibitor treatment has stopped working.
This trial tests a new drug called sacituzumab tirumotecan for people with triple-negative breast cancer that has spread to the brain. It may help shrink brain tumors and improve outcomes for those who have not responded to previous treatments.
This trial tests a new way of giving an experimental drug directly into the fluid around the brain and spinal cord for people whose lung cancer has spread there and stopped responding to targeted therapy. The goal is to see if it can shrink or control the cancer in this area and help with symptoms.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.